The mergers and acquisitions market has already seen a flurry of deals at the start of 2025 across sectors. Here's a look at ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

County Public Schools has joined dozens of other school systems and institutions in suing pharmaceutical and pharmacy companies, alleging that the companies manipulated the prices of insulin and other ...

Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...

Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.